company background image
GHRS logo

GH Research NasdaqGM:GHRS Stock Report

Last Price

US$7.09

Market Cap

US$368.9m

7D

-16.2%

1Y

28.9%

Updated

24 Dec, 2024

Data

Company Financials +

GHRS Stock Overview

Together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. More details

GHRS fundamental analysis
Snowflake Score
Valuation1/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

My Notes

Capture your thoughts, links and company narrative

GH Research PLC Competitors

Price History & Performance

Summary of share price highs, lows and changes for GH Research
Historical stock prices
Current Share PriceUS$7.09
52 Week HighUS$14.99
52 Week LowUS$5.12
Beta0.78
1 Month Change-23.52%
3 Month Change-2.74%
1 Year Change28.91%
3 Year Change-69.51%
5 Year Changen/a
Change since IPO-63.17%

Recent News & Updates

We're Hopeful That GH Research (NASDAQ:GHRS) Will Use Its Cash Wisely

Oct 11
We're Hopeful That GH Research (NASDAQ:GHRS) Will Use Its Cash Wisely

We're Hopeful That GH Research (NASDAQ:GHRS) Will Use Its Cash Wisely

Jun 21
We're Hopeful That GH Research (NASDAQ:GHRS) Will Use Its Cash Wisely

GH Research (NASDAQ:GHRS) Is In A Good Position To Deliver On Growth Plans

Mar 01
GH Research (NASDAQ:GHRS) Is In A Good Position To Deliver On Growth Plans

Recent updates

We're Hopeful That GH Research (NASDAQ:GHRS) Will Use Its Cash Wisely

Oct 11
We're Hopeful That GH Research (NASDAQ:GHRS) Will Use Its Cash Wisely

We're Hopeful That GH Research (NASDAQ:GHRS) Will Use Its Cash Wisely

Jun 21
We're Hopeful That GH Research (NASDAQ:GHRS) Will Use Its Cash Wisely

GH Research (NASDAQ:GHRS) Is In A Good Position To Deliver On Growth Plans

Mar 01
GH Research (NASDAQ:GHRS) Is In A Good Position To Deliver On Growth Plans

GH Research (NASDAQ:GHRS) Is In A Good Position To Deliver On Growth Plans

Nov 17
GH Research (NASDAQ:GHRS) Is In A Good Position To Deliver On Growth Plans

GH Research (NASDAQ:GHRS) Is In A Good Position To Deliver On Growth Plans

Jul 30
GH Research (NASDAQ:GHRS) Is In A Good Position To Deliver On Growth Plans

We're Hopeful That GH Research (NASDAQ:GHRS) Will Use Its Cash Wisely

Mar 13
We're Hopeful That GH Research (NASDAQ:GHRS) Will Use Its Cash Wisely

Companies Like GH Research (NASDAQ:GHRS) Are In A Position To Invest In Growth

Nov 28
Companies Like GH Research (NASDAQ:GHRS) Are In A Position To Invest In Growth

GH Research GAAP EPS of $0.006

Aug 23

We Think GH Research (NASDAQ:GHRS) Can Afford To Drive Business Growth

Aug 15
We Think GH Research (NASDAQ:GHRS) Can Afford To Drive Business Growth

GH Research (NASDAQ:GHRS) Is In A Good Position To Deliver On Growth Plans

Apr 29
GH Research (NASDAQ:GHRS) Is In A Good Position To Deliver On Growth Plans

We're Not Very Worried About GH Research's (NASDAQ:GHRS) Cash Burn Rate

Jan 13
We're Not Very Worried About GH Research's (NASDAQ:GHRS) Cash Burn Rate

GH Research (NASDAQ:GHRS) Is In A Good Position To Deliver On Growth Plans

Sep 30
GH Research (NASDAQ:GHRS) Is In A Good Position To Deliver On Growth Plans

GH Research: A Recent IPO Stock That Could Possibly Be A Trailblazer In A Hot Industry

Aug 15

Shareholder Returns

GHRSUS PharmaceuticalsUS Market
7D-16.2%1.6%-2.2%
1Y28.9%9.7%23.9%

Return vs Industry: GHRS exceeded the US Pharmaceuticals industry which returned 9.7% over the past year.

Return vs Market: GHRS exceeded the US Market which returned 23.9% over the past year.

Price Volatility

Is GHRS's price volatile compared to industry and market?
GHRS volatility
GHRS Average Weekly Movement10.9%
Pharmaceuticals Industry Average Movement10.4%
Market Average Movement6.3%
10% most volatile stocks in US Market17.0%
10% least volatile stocks in US Market3.1%

Stable Share Price: GHRS's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: GHRS's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
201849Villy Valchevawww.ghres.com

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). The company’s lead program is GH001, an inhalable mebufotenin product candidate, currently under Phase 2b clinical trial for the treatment of patients with TRD, as well as Phase 2a clinical trials for the treatment of Bipolar II disorder and postpartum depression.

GH Research PLC Fundamentals Summary

How do GH Research's earnings and revenue compare to its market cap?
GHRS fundamental statistics
Market capUS$368.88m
Earnings (TTM)-US$41.43m
Revenue (TTM)n/a

0.0x

P/S Ratio

-8.9x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
GHRS income statement (TTM)
RevenueUS$0
Cost of RevenueUS$0
Gross ProfitUS$0
Other ExpensesUS$41.43m
Earnings-US$41.43m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-0.80
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0%

How did GHRS perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/24 22:16
End of Day Share Price 2024/12/24 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

GH Research PLC is covered by 6 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Sumant Satchidanand KulkarniCanaccord Genuity
Patrick TrucchioH.C. Wainwright & Co.
Jason ButlerJMP Securities